Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9620 added to oral antivirals for chronic hepatitis B
ACTRN12614000628640Phase 2Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of vesatolimod in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
vesatolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ACTRN12614000628640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12614000628640.